Related Experiment Video
Updated: Jan 30, 2026

Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
Published on: March 3, 2023
[Analysis of changes in serological factors in the dose-increasing phase of allergic rhinitis rush immunotherapy]
1Department of Otorhinolaryngology Head and Neck Surgery,the Second Affiliated Hospital of Nanchang University,Nanchang,330006,China.
Abstract:
Objective:To observe the changes of serological factors in the dose-increasing phase of allergic rhinitis and to explore the mechanism of short-term rush immunotherapy.Method:The clinical data of 110 patients with allergic rhinitis diagnosed by rush immunotherapy in our hospital were analyzed. According to the results of allergen test(sIgE), they were divided into simple dust mite allergy group and multiple allergen allergy groups. The serum of the patients were taken before the start of rush immunotherapy and the first day after the end of the dose-increasing phase.Serum total IgE and IgG before and after rush immunotherapy were detected by Beekman specific protein detector. The serum levels of IFN-γ,IL-12,IL-10,IgG1 and IgG4 were measured by ELISA before and after rush immunotherapy. The changes of them were compared and analyzed.Result:①Serum total IgE and IgG were increased after rush immunotherapy, and the change of serum IgG concentration in the simple dust mite allergy group was statistically significant(P<0.05).②The levels of serum IFN-γ, IL-12 and IL-10 increased after rush immunotherapy. The changes of IL-12 and IFN-γ in multiple allergen allergy groups were not significant before and after treatment, while the changes in other groups were statistically significant(P<0.05).③Serum total IgG1 and IgG4 were increased after rush immunotherapy. The changes of serum IgG4 in the simple dust mite allergy group were statistically significant(P<0.05). There was no statistically significant difference in serum IgG1.Conclusion:The dose-increasing phase of rush immunotherapy can stimulate the production of IgG antibodies and the changes of related serological factors in a short period of time, especially in patients with simple dust mite allergy group. It indicates that dose-increasing phase of rush immunotherapy may play a role by regulating immunoglobulin and adjusting the dynamic balance of Th1/Th2 factors.
Related Concept Videos
Allergic Reactions
Tumor Immunotherapy
Phase Transitions
Allergic Drug Reactions
Increasing Function
Phase Diagrams

